Loading clinical trials...
Loading clinical trials...
A Randomized, Multiple-Dose,Double-Blind,Crossover Trial to Assess the Systemic Exposure of Fluticasone Propionate (FP)/Formoterol Fumarate (FF) Fixed-Dose Combination in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the systemic exposure and pharmacodynamics of two doses of nebulized fluticasone/formoterol combination as compared to the monocomponents.
Age
40 - No limit years
Sex
ALL
Healthy Volunteers
No
Investigative Site
San Diego, California, United States
Investigative Site
Panama City, Florida, United States
Investigative Site
Madisonville, Kentucky, United States
Investigative Site
Sunset, Louisiana, United States
Investigative Site
Charlotte, North Carolina, United States
Investigative Site
Medford, Oregon, United States
Investigative Site
Greenville, South Carolina, United States
Investigative Site
Spartanburg, South Carolina, United States
Investigative Site
Union, South Carolina, United States
Investigative Site
San Antonio, Texas, United States
Start Date
November 1, 2008
Primary Completion Date
April 1, 2009
Completion Date
May 1, 2009
Last Updated
May 20, 2013
97
ACTUAL participants
fluticasone propionate/formoterol fumarate
DRUG
fluticasone propionate
DRUG
formoterol fumarate
DRUG
Lead Sponsor
Dey
NCT07477600
NCT05878769
NCT06717659
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions